Compare Quantumscape Corp (QS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantumscape Corp vs TG Therapeutics Inc — how do they compare? Quantumscape Corp trades at $5.26 (market cap $3.44B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: TG Therapeutics Inc is far larger — about 2.5× Quantumscape Corp's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals.
| QS | TGTX | |
|---|---|---|
Market Cap | $3.44B | $8.53B |
Sector | Consumer Cyclical | Health |
52-Week High | $18.44 | $59.06 |
52-Week Low | $4.89 | $26.94 |
Enterprise Value | $2.65B | $8.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QuantumScape trades at $5.59, up 2.01% today but near 52-week lows, with a bearish technical signal from moving averages. The company is pre-revenue, reporting a net loss of $435.05M in 2025, negative ROE of -39.08%, and cash burn from operations. Recent news highlights insider sales and delayed commercialization timelines, with solid-state battery production not expected until 2029.
Outlook remains speculative with high execution risk; analyst consensus is cautious (0% buy, 73% hold, 27% sell). Investment hinges on successful battery commercialization by 2029, but competition and funding needs pose significant threats to shareholder value amid persistent losses.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
